| Overview |
| bsm-61491r-apc-cy5-100ul |
| WNT5A Recombinant Monoclonal Antibody, APC-Cy5 Conjugated |
| WB, FCM, IF(ICC) |
| Human |
| Specifications |
| APC-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Wnt5a |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7474 |
| P41221 |
| Extracellular, Secreted |
| hWNT5A; Protein Wnt5a; Wingless type MMTV integration site family member 5A; WNT 5A protein; WNT 5A protein precursor; WNT5A. |
| Ligand for members of the frizzled family of seven transmembrane receptors. Can activate or inhibit canonical Wnt signaling, depending on receptor context. In the presence of FZD4, activates beta-catenin signaling. In the presence of ROR2, inhibits the canonical Wnt pathway by promoting beta-catenin degradation through a GSK3-independent pathway which involves down-regulation of beta-catenin-induced reporter gene expression. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz